| Literature DB >> 19735261 |
Tamara Intermesoli1, Federica Delaini, Sara Acerboni, Silvia Salmoiraghi, Orietta Spinelli, Vittoria Guerini, Alessandro M Vannucchi, Silvia Mappa, Giuseppe Rossi, Valentina Rossi, Eros Di Bona, Simona Paratore, Alessandra Carobbio, Alessandro Rambaldi, Tiziano Barbui, Renato Bassan.
Abstract
Although imatinib may be effective in hypereosinophilic syndromes, the exact response kinetics are not known. Imatinib was administered at 100-400 mg/d each week in a 12-week response-oriented schedule, targeting a complete clinical and haematological remission (CR). CR was achieved in 11/23 patients (6/6 with FIP1L1-PDGRFA rearrangement and 5/17 without, P = 0.006), most after 2 weeks of 100 mg/d imatinib. The maximum imatinib dose had no effect in early unresponsive patients. Low-dose, short-course imatinib may represent a rational choice for identifying responsive cases, both within and outside the pre-defined FIP1L1 rearrangement subset.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19735261 DOI： 10.1111/j.1365-2141.2009.07893.x
Source DB: PubMed Journal: Br J Haematol ISSN： 0007-1048 Impact factor: 6.998